Amgen Inc. (formerly Applied Molecular Genetics Inc.) is one of the world’s largest independent biotechnology companies established at Thousand Oaks, California, in 1980.
- In Mar 2021, Amgen acquired Five Prime Therapeutics in approx. $1.9 billion. Five Prime’s lead asset, bemarituzumab, is a first-in-class, Phase 3 ready anti-FGFR2b antibody with positive data from a randomized, placebo-controlled Phase 2 study in frontline advanced gastric or gastroesophageal junction (GEJ) cancer.
- In Oct 2019, Amgen acquired 20.5% Stake in BeiGene for approx. $2.7 Billion in Cash.
- In May 2019, Amgen, acquired Scandinavian biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 Mn). Nuevolution has developed Chemetics, a patent protected DNA-encoded library drug discovery platform, which enables discovery of novel small molecule drug candidates.
- In Oct 2017, Amgen acquired Kirin-Amgen, a joint venture company in $780 Mn USD and make a wholly-owned subsidiary of Amgen. Kirin-Amgen was established in 1984 as a 50-50 joint venture between Amgen and Kirin to fund the global development of EPOGEN® (epoetin alfa). Over time, the scope of the collaboration was expanded to include NEUPOGEN® (filgrastim), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Nplate® (romiplostim) and brodalumab. Kirin-Amgen holds the intellectual property for each of these products and, in exchange for royalty rights, licensed the associated marketing rights in certain Asian countries to Kyowa Hakko Kirin (KHK), Kirin’s pharmaceutical subsidiary, and in other territories to Amgen.
- In 2013, Amgen acquired Onyx Pharmaceuticals, in $9.7 billion USD and makes it a wholly owned subsidiary.
- In 2012, Amgen acquired Micromet, for $1.16 billion USD and makes it, its wholly owned subsidiary (named as Amgen Research (Munich) GmbH. It was developing product portfolio based on its proprietary BiTE® (Bispecific T Cell Engager) antibody platform. Micromet was in collaboration with MedImmune, for the development of new BiTE molecules targeting carcinoembryonal antigen.
- In Mar 2011, Amgen acquired BioVex, developing OncoVEX™, an oncolytic vaccine in PH III clinical development, against melanoma in approx. $1 billion USD and makes it its wholly owned subsidiary.
- In Apr 2006, Amgen acquired Abgenix, a biopharmaceutical company developing mAbs against cancer, for approx. $2.2 billion USD.